Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia

1 Oct 2016

Abstract excerpt

Acute myeloid leukemia (AML) is an aggressive cancer with a poor prognosis, for which mainstream treatments have not changed for decades. To identify additional therapeutic targets in AML, we optimize a genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screening platform and use it to identify genetic vulnerabilities in AML cells. We identify 492 AML-specific cell-essential genes,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to CRISPR and Genetic Engineering
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27760321
DOI: 10.1016/j.celrep.2016.09.079

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid LeukemiaPMID 27760321Read ↗

Identification of novel genetic vulnerabilities and therapeutic targets in acute myeloid leukaemia using CRISPR dropout screensSemantic proximity Read ↗

An in vivo CRISPR screening platform for prioritizing therapeutic targets in AMLSemantic proximity Read ↗

The high-performance technology CRISPR/Cas9 improves knowledge and management of acute myeloid leukemia.Semantic proximity Read ↗

Integrating Human Genetics and Protective Genome Editing to Enable ADGRE2-Directed AML TherapySemantic proximity Read ↗

CRISPR-based functional genomics for dissecting therapeutic dependency in primary acute myeloid leukemia samples.Semantic proximity Read ↗

Identification of GTF2IRD1 as a novel transcription factor essential for acute myeloid leukemiaSemantic proximity Read ↗

In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic TargetSemantic proximity Read ↗

Functional Dependency Analysis Identifies Potential Druggable Targets in Acute Myeloid LeukemiaSemantic proximity Read ↗

Large-Scale In Vitro and In Vivo CRISPR-Cas9 Knockout Screens Identify a 16-Gene Fitness Score for Improved Risk Assessment in Acute Myeloid LeukemiaSemantic proximity Read ↗

Whole genome and transcriptome analysis of a novel AML cell line with a normal karyotype.Semantic proximity Read ↗

Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AMLSemantic proximity Read ↗

Unbiased functional genetic screens reveal essential RNA modifications in human cancer and drug resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.